Literature DB >> 2686882

Clinical pharmacokinetics of ceftriaxone.

J H Yuk1, C H Nightingale, R Quintiliani.   

Abstract

Ceftriaxone is a third-generation cephalosporin that exhibits saturable plasma protein binding, which influences its pharmacokinetic parameters depending on the dose. Systemic clearance and volume of distribution of total drug show dependence on both concentration and time, whereas for unbound drug these parameters remain constant. The decrease in renal or non-renal clearance with age or in the presence of disease states is often compensated by the concurrent increase in free fraction, resulting in no apparent changes in half-life and no need for dose adjustment. Because of its unusually long plasma half-life, the availability of intramuscular administration and its high intrinsic activity against many organisms, ceftriaxone has become a popular agent in once-daily therapy of infections in paediatric patients, gonococcal infections and outpatient management of pneumonia and osteomyelitis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686882     DOI: 10.2165/00003088-198917040-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  133 in total

1.  Ceftriaxone pharmacokinetics in the central nervous system.

Authors:  R Spector
Journal:  J Pharmacol Exp Ther       Date:  1986-02       Impact factor: 4.030

Review 2.  International experiences with ceftriaxone in the treatment of lower respiratory tract infections.

Authors:  C Grassi; P Mangiarotti
Journal:  Chemioterapia       Date:  1987-10

3.  Ceftriaxone treatment of multidrug-resistant Salmonella osteomyelitis.

Authors:  J W Sherman; J E Conte
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

4.  Variability of ceftriaxone pharmacokinetics in hospitalized patients with severe infections.

Authors:  B Joos; R Luethy; E Muehlen; W Siegenthaler
Journal:  Am J Med       Date:  1984-10-19       Impact factor: 4.965

5.  Once-daily ceftriaxone for skin and soft tissue infections.

Authors:  F M Gordin; C B Wofsy; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

6.  Single-dose ceftriaxone for chancroid.

Authors:  M I Bowmer; H Nsanze; L J D'Costa; J Dylewski; L Fransen; P Piot; A R Ronald
Journal:  Antimicrob Agents Chemother       Date:  1987-01       Impact factor: 5.191

7.  Comparative study of ceftriaxone and trimethoprim-sulfamethoxazole for the treatment of chancroid in Thailand.

Authors:  D N Taylor; C Pitarangsi; P Echeverria; K Panikabutra; C Suvongse
Journal:  J Infect Dis       Date:  1985-11       Impact factor: 5.226

8.  Ceftriaxone kinetics and cerebrospinal fluid penetration in infants and children with meningitis.

Authors:  M C Nahata; D E Durrell; W J Barson
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

9.  Comparative in vitro activity of 8 cephalosporins on 109 strains of Neisseria gonorrhoeae and 60 strains of Neisseria meningitidis.

Authors:  A Thabaut; J L Durosoir; P Saliou
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

10.  Susceptibility of penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae isolated in Durban, South Africa, to 15 beta-lactam antibiotics.

Authors:  Y M Coovadia; J Van den Ende; A A Hoosen; A Kharsany
Journal:  Sex Transm Dis       Date:  1988 Jan-Mar       Impact factor: 2.830

View more
  22 in total

Review 1.  Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases.

Authors:  P S McKinnon; S L Davis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-10       Impact factor: 3.267

2.  Effect of protein binding on the pharmacological activity of highly bound antibiotics.

Authors:  Stephan Schmidt; Katharina Röck; Martina Sahre; Olaf Burkhardt; Martin Brunner; Maximilian T Lobmeyer; Hartmut Derendorf
Journal:  Antimicrob Agents Chemother       Date:  2008-09-08       Impact factor: 5.191

3.  Reversal of Borrelia burgdorferi associated dilated cardiomyopathy by antibiotic treatment?

Authors:  R Gasser; F Fruhwald; M Schumacher; G Seinost; E Reisinger; B Eber; A Keplinger; R Horvath; B Sedaj; W Klein; K Pierer
Journal:  Cardiovasc Drugs Ther       Date:  1996-07       Impact factor: 3.727

4.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

5.  "Effect of Subinhibitory Concentrations of Some Antibiotics and Low Doses of Gamma Radiation on the Cytotoxicity and Expression of Colibactin by an Uropathogenic Escherichia coli isolate".

Authors:  Radwa N Morgan; Hala A Farrag; Mohammad M Aboulwafa; Sarra E Saleh
Journal:  Curr Microbiol       Date:  2021-01-03       Impact factor: 2.188

Review 6.  Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.

Authors:  Harriet M Lamb; Douglas Ormrod; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Considerations in dosage selection for third generation cephalosporins.

Authors:  J H Yuk-Choi; C H Nightingale; T W Williams
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

8.  Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis.

Authors:  Yanli Zhao; Merit E Cudkowicz; Jeremy M Shefner; Lisa Krivickas; William S David; Francine Vriesendorp; Alan Pestronk; James B Caress; Jonathan Katz; Ericka Simpson; Jeffrey Rosenfeld; Robert Pascuzzi; Jonathan Glass; Kourosh Rezania; Jerold S Harmatz; David Schoenfeld; David J Greenblatt
Journal:  J Clin Pharmacol       Date:  2014-05-16       Impact factor: 3.126

Review 9.  Clinical use of ceftriaxone: a pharmacokinetic-pharmacodynamic perspective on the impact of minimum inhibitory concentration and serum protein binding.

Authors:  T R Perry; J J Schentag
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

10.  Pharmacokinetics and protein binding of ceftriaxone during pregnancy.

Authors:  P Bourget; H Fernandez; V Quinquis; C Delouis
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.